COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.

Mid- to late October is the best time to get flu and COVID vaccines, so they will be effective during November and December holiday gatherings.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.14 which represents a decrease of $-0.04 or -0.39% from the prior close of $10.18. The stock opened at $10.1 and touched a low ...

Depending on when you last got vaccinated, that COVID-19 shot may no longer be a good match for the variants expected to ...

However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novavax announced Wednesday that the Food and Drug Administration (FDA) has placed a clinical hold on its application for a ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.